A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

INTRODUCTION: Bevacizumab and gemcitabine are key drugs for treating recurrent epithelial ovarian cancer. However, information about the combination of bevacizumab and gemcitabine is insufficient. We conducted a phase II study to assess the feasibility, clinical activity, and toxicity of this combin...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Ovarian Res
Autori principali: Nagao, Shoji, Kogiku, Ai, Suzuki, Kazuhiro, Shibutani, Takashi, Yamamoto, Kasumi, Jimi, Tomoatsu, Kitai, Miho, Shiozaki, Takaya, Matsuoka, Kazuko, Yamaguchi, Satoshi
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2020
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7006142/
https://ncbi.nlm.nih.gov/pubmed/32028974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13048-020-0617-y
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi